Open an account

Xtant Medical Holdings

XTNT · NYSE American

$0.303+$0.012 (+4.12%)TodayMarket closed ·
Prev close $0.291

About XTNT

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 151 full-time employees. The company went IPO on 2010-06-30. The firm's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The firm has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.

Employees
151
Headquarters
Belgrade Montana, Montana
Listed
Jun 30, 2010
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
xtantmedical.com

XTNT key statistics

Market cap
60.65M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
151.66K
Volume
87.90K
Open price
$0.30
High today
$0.3069
Low today
$0.283
52 Week high
$0.95
52 Week low
$0.2702

Xtant Medical Holdings (XTNT) at a glance

As of Oct 20, 2026, Xtant Medical Holdings (XTNT) shares are priced at $0.303, giving the company a market cap of 60.65M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.283 and $0.3069. The current price is 7.1% above the day's low and 1.3% below its high.

Volume so far is 87.90K shares, below the average of 151.66K shares a day.

Over the past year Xtant Medical Holdings has ranged from $0.2702 to $0.95, and now sits 5% of the way up that range.

Xtant Medical Holdings met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.03 per share against an estimate of -$0.0204.

The average analyst price target is $1.05, 247.8% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $1.05
Low
$0.606
Now
$0.303
High
$1.58

XTNT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 198.0% on average.

  1. Q3 FY24: reported -$0.04 per share against an estimate of -$0.0255
  2. Q4 FY24: reported -$0.02 per share against an estimate of -$0.0153
  3. Q1 FY25: reported $0.00 per share against an estimate of -$0.0102
  4. Q2 FY25: reported $0.02 per share against an estimate of -$0.0102
  5. Q3 FY25: reported $0.01 per share against an estimate of -$0.0051
  6. Q4 FY25: reported $0.00 per share against an estimate of -$0.0051
  7. Q1 FY26: reported -$0.02 per share against an estimate of -$0.017
  8. Q2 FY26: reported -$0.03 per share against an estimate of -$0.0204

XTNT news

  • Press releasePRNewswire

    Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    Xtant Medical Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026

  • Press releasePRNewswire

    Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference

  • Press releasePRNewswire

    Xtant Medical Reports First Quarter 2026 Financial Results

  • Press releasePRNewswire

    Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026

Similar companies

Companies in the same industry as Xtant Medical Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.